Vela Genomics NGS Clinical Interpretation and Reporting

Vela Genomics, a subsidiary of Vela Diagnostics, has launched TheraKey, a cloud-based, HIPAA-compliant, next-generation sequencing clinical interpretation and reporting solution. The TheraKey database includes somatic cancer mutations in more than 800 genes, sourced from approximately 220,000 clinical trials for about 2,000 cancer drugs. It also offers natural language processing to facilitate reporting of actionable treatments, including off-label, investigational, and combination therapies for specific diseases or gene variants. The firm will also offer TheraKey as part of its Sentosa NGS workflow for Oncology.